Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-02
2007-10-02
Seaman, Margaret D. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S414000, C514S418000, C514S404000, C546S113000, C546S277100, C548S469000, C548S361100
Reexamination Certificate
active
10596495
ABSTRACT:
Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith
REFERENCES:
patent: 4973587 (1990-11-01), Ward et al.
patent: 5013837 (1991-05-01), Ward et al.
patent: 5081122 (1992-01-01), Ward
patent: 5112820 (1992-05-01), Ward
patent: 5292736 (1994-03-01), Kumar et al.
patent: 5532237 (1996-07-01), Gallant et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 6028084 (2000-02-01), Barth et al.
patent: 2002/0119972 (2002-08-01), Leftheris et al.
patent: 2003/0114495 (2003-06-01), Finke et al.
patent: 2003/0119810 (2003-06-01), Achard et al.
patent: 0 658 546 (2001-05-01), None
patent: 1 506 960 (2005-02-01), None
patent: WO 96/25397 (1996-08-01), None
patent: WO96/25397 (1996-08-01), None
patent: WO97/29079 (1997-08-01), None
patent: WO 97/29079 (1997-08-01), None
patent: WO 98/31227 (1998-07-01), None
patent: WO98/31227 (1998-07-01), None
patent: WO98/37061 (1998-08-01), None
patent: WO 98/37061 (1998-08-01), None
patent: WO 98/41519 (1998-09-01), None
patent: WO98/41519 (1998-09-01), None
patent: WO 98/43635 (1998-10-01), None
patent: WO98/43635 (1998-10-01), None
patent: WO 98/43636 (1998-10-01), None
patent: WO98/43636 (1998-10-01), None
patent: WO 99/02499 (1999-01-01), None
patent: WO99/02499 (1999-01-01), None
patent: 00/30683 (2000-02-01), None
patent: WO 00/10967 (2000-03-01), None
patent: WO 00/10968 (2000-03-01), None
patent: WO 03/026648 (2003-04-01), None
patent: WO 03/027076 (2003-04-01), None
Kuster, et al., “Aminoalkylindole Binding in Rat Cerebellum : Selective Displacement by Natural and Synthetic Cannabinoids”The J. Pharmacology and Experimental Therapeutics, vol. 264., 3, 1352-1363 (1993).
Little, et al., “Pharmacology and Stereoselectivity of Structurally Novel Cannabinoids in Mice1”.The J. Pharmacology and Experimental Therapeutics, vol. 247., 3, 1046-1051 (1988).
Rinaldi-Carmona, et al “SR141716A, a potent and selective antagonist of the brain cannabinoid receptor”,FEBS Letter, vol. 350, 240-244 (1994).
Portier, et al., “SR 144528, an Antagonist for the Peripheral Cannabinoid Receptor that Behaves as an Inverse Agonist”The J. Pharmacology and Experimental Therapeuticsvol. 288, 2 (1999).
Rinaldi-Carmona, et al., “Biochemical and Pharmacological Charcterisation of SR141716A, The First Potent and Selective Brain Cannabinoid Receptor Antagonist”,Life Science, vol. 56, 23/24, 1941-1947 (1995).
STN File Registry, RN394228-83-2 (2000).
STN File Registry, RN394228-8-4 (2000).
STN File Registry, RN 439128-75-3 (2000).
Kuster, et al., “Aminoalkylindole Binding in Rat Cerebellum : Selective Displacement by Natural and Synthetic Cannabinoids”The J. Pharmacology and Experimental Therapeutics, vol. 264., 3, 1352-1363 (1993).
Little, et al., “Pharmacology and Stereoselectivity of Structurally Novel Cannabinoids in Mice1”.The J. Pharmacology and Experimental Therapeutics, vol. 247., 3, 1046-1051 (1988).
Rinaldi-Carmona, et al “SR141716A, a potent and selective antagonist of the brain cannabinoid receptor”,FEBS Letter, vol. 350, 240-244 (1994).
Portier, et al., “SR 144528, an Antagonist for the Peripheral Cannabinoid Receptor that Behaves as an Inverse Agonist”The J. Pharmacology and Experimental Therapeuticsvol. 288, 2 (1999).
Rinaldi-Carmona, et al., “Biochemical and Pharmacological Charcterisation of SR141716A, The First Potent and Selective Brain Cannabinoid Receptor Antagonist”,Life Science, vol. 56, 23/24, 1941-1947 (1995).
STN File Registry, RN394228-83-2 (2000).
STN File Registry, RN394228-8-4 (2000).
STN File Registry, RN 439128-75-3 (2000).
Allen Jennifer Rebecca
Amegadzie Albert Kudzovi
Gardinier Kevin Matthew
Gregory George Stuart
Hitchcock Steven Andrew
Cleveland, Jr. John A.
Eli Lilly and Company
Grayson Angela J.
Rahmani Niloofar
Seaman Margaret D.
LandOfFree
CB1 antagonist compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CB1 antagonist compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CB1 antagonist compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3882279